Table 3 Annual transition probabilities for ranibizumab and no ranibizumab treatment strategies for first two years
From: Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
| Â | Difference in number of letters read on logMAR chart at beginning and end of year | |||||||
|---|---|---|---|---|---|---|---|---|
| Â | Ranibizumab treatment | No ranibizumab treatment | ||||||
Year | 15 | 0 | -15 | -30 | 15 | 0 | -15 | -30 |
1 | 0.338 | 0.608 | 0.042 | 0.012 | 0.050 | 0.572 | 0.235 | 0.143 |
2 | 0.030 | 0.902 | 0.051 | 0.017 | 0.000 | 0.848 | 0.070 | 0.082 |